## Oza Zaheed Maheswaran

Address : Cork

Nationality : Irish


### Education :

_2021 - Current_	
- PhD Candidate 2nd Year
- University College Cork, Cork, Ireland
- Supervisor : Dr Kellie Dean (Primary), Prof Pasha Baranov 
- Thesis : Cancer proteogenomics – identifying bifunctional RNAs relevant in cancer progression or drug resistance

_2019 – 2020_	
- MSc in Bioinformatics and Computational Biology
- University College Cork, Ireland
- Graduated with 1st Class Honours

_2003 – 2008_	
- Bachelor of Medicine & Bachelor of Surgery & Bachelor of Obstetrics
- National University of Ireland Galway, Ireland


### Previous Employment History :

_July 2013 – July 2018_	
- Registrar (Doctor) – Radiation and Medical Oncology
- In this position, I performed a senior role in both inpatient and outpatient services. Responsibilities included but were not limited to radiotherapy treatment planning (Deep Inspiration Breath Holding Technique, 4D Radiotherapy, External Beam Radiotherapy, Brachytherapy), radionuclide administration and palliative treatment. 

_Jan 2010 – July 2013_	
- Senior House Officer (Doctor) – Radiation Oncology, Surgical
- Performed in an intermediate position within the clinical team for both inpatient and outpatient services. Responsibilities also included assistance in major theatre, endoscopy suite and minor theatre.

_Jan 2009 – Jan 2010_	
- Intern (Doctor) – General Medicine, Surgical
- Junior role in the clinical team. Responsibilities primarily involved inpatient services. Involved in outpatient clinics for 				outpatient services. 


### Awards :

_2021 James Taylor Fellowship_ 
- Awarded to attend the Galaxy Community Conference and Training Week 

_2020 Science Foundation Ireland, Centre for Research Training_		
- Recruited into the second cohort of the PhD programme for Genomics Data Science
		
_2003 Majlis Amanah Rakyat Scholarship_
- Awarded to pursue a Medical Degree at National University of Ireland Galway


### Publications :

1. **Zaheed O**, Kiniry SJ, Baranov PV and Dean K (2021). Exploring Evidence of Non-coding RNA Translation With Trips-Viz and GWIPS-Viz Browsers. Front. Cell Dev. Biol. 9:703374. doi: 10.3389/fcell.2021.703374

2. Samson J, Derlipanska M, **Zaheed O** et al. BMC Cancer 21, 790 (2021). Molecular and cellular characterization of two patient-derived ductal carcinoma in situ (DCIS) cell lines, ETCC-006 and ETCC-010. https://doi.org/10.1186/s12885-021-08511-2

3. **Zaheed O**, Samson J, Dean K (2020). A bioinformatics approach to identify novel long, non-coding RNAs in breast cancer cell lines from an existing RNA-sequencing dataset. Non-coding RNA Research, Volume 5, Issue 2, 2020, Pages 48-59, ISSN 2468-0540. https://doi.org/10.1016/j.ncrna.2020.02.004


### Presentations :

_2016 Annual Scientific Meeting (Radiation Oncology)_
- “Factors influencing psychological adjustments in patients with a diagnosis of Ductal Carcinoma in Situ (DCIS)”

_2014 Irish Society of Medical Oncology National Travel Bursaries_ 
- “Risk of Pathological Fractures in Solitary Bone Plasmacytoma : Illustrated Case Report”


### Posters :

_2019 New Horizons Research Conference_ 
- “Bioinformatics Analysis of Breast Cancer Cell Line RNA Sequencing Data to Assess Expression of Long Non-Coding Transcripts”

_2015 Annual Scientific Meeting (Radiation Oncology)_ 
- “Plantar Fasciitis and Radiotherapy : A Single Institution Experience”

_2014 Annual Scientific Meeting (Radiation Oncology)_ 
- “Prostate Biopsy : The Transperineal Approach”


### Trials :

_Role : Sub-Investigator_

1. Prospective Phase II Dose Escalation Study using IMRT for High Risk N0M0 Prostate Cancer. ICORG 08-17

2. Randomised Phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in-situ (DCIS) of the breast. BIG 3-07 / TROG 07.01

3. Neo-AEGIS (NEOadjuvant trial in Adenocarcinoma of the Oesophagus and oesophagogastric junction International Study): Randomised Clinical Trial of neoadjuvant and adjuvant chemotherapy (Modified MAGIC regimen) vs. neoadjuvant chemoradiation (CROSS protocol) in adenocarcinoma of the oesophagus and oesophago-gastric junction. ICORG 10-14
Phase II Single-arm Study evaluating Neo-adjuvant (pre-radical radiotherapy) Abiraterone acetate (plus prednisolone) and Gonadotropin-Releasing Hormone (GnRH) agonist in High Risk Localised Prostate Carcinoma. CTRIAL-IE (ICORG) 13-23

4. Phase II Study of Radium-223 in Combination with Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer. ICORG 13-21

5. Randomised Phase III trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk,clinically localised,prostate cancer: ENZARAD. ICORG14-07

6. Randomised open label Phase III trial evaluating the addition of Denosumab to standard first line anticancer treatment in advanced NSCLCa : SPLENDOUR. EORTC 08111

7. Phase II randomized double blinded placebo controlled trial of radium 223 dichloride vs. placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases treated with hormonal treatment background therapy. BAY 88-8223/16298


### Professional Society Membership :

- Member of the European Association for Cancer Research (EACR)


### References :

**1. Dr Kellie Dean**				
- School of Biochemistry and Cell Biology
- 3.91 Western Gateway Building, Western Road
- University College Cork 
- Cork, Ireland T12 XF62

**2. Pasha Baranov**			
- Professor of Biomolecular Informatics, MRIA
- SFI-HRB-Wellcome Trust Investigator
- School of Biochemistry and Cell Biology
- University College Cork 
- Cork, Ireland 
- http://lapti.ucc.ie
			
